Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents

Hepatology

Volumn 24, Issue 5, 1996, Pages 1010-1017

  Scaglioni, Paolo ^a   Melegari, Margherita ^a   Takahashi, Minoru ^b   Chowdhury, Jayanta Roy ^b   Wands, Jack ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ANTIVIRUS AGENT; COMPLEMENTARY DNA; CORE PROTEIN; VIRUS ANTIGEN;

ANIMAL CELL; ARTICLE; CHICKEN; CHRONIC HEPATITIS; DNA REPLICATION; GENE THERAPY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MUTANT; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOUTHERN BLOTTING; VIRUS REPLICATION;

EID: 0029953004     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.1996.v24.pm0008903368     Document Type: Article

References (35)

1. McLachlan, A. Molecular biology of the hepatitis B virus. Boca Raton, FL: CRC, 1991.
2. Lau JYN, Wright TL. Molecular virology and pathogenesis of hepatitis B. Lancet 1993;343:1335-1344.
3. Wands JR, Blum HE. Primary hepatocellular carcinoma. N Engl J Med 1991;325:729-731.
4. Hoofnagle JH. Therapy of acute and chronic viral hepatitis. Adv Intern Med 1994;39:241-275.
5. Goodarzi G, Gross SC, Tewari A, Watanabe K. Antisense oligodeoxyribonucleotides inhibit the expression of the gene for hepatitis B virus surface antigen. J Gen Virol 1990;71:3021-3125.
6. Blum HE, Galun E, von Weizsäcker F, Wands JR. Inhibition of hepatitis B virus by antisense oligodeoxynucleotides [Letter]. Lancet 1991;337:1230.
7. von Weizsäcker F, Blum HE, Wands JR. Cleavage of hepatitis B virus RNA by three ribozymes transcribed from a single DNA template. Biochem Biophys Res Commun 1992;189:743-748.
8. Offensperger WB, Offensperger S, Walker E, Teubner K, Igloi G, Blum HE, Gerok W. In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. EMBO J. 1993;12:1257-1262.
9. Trono D, Feinberg MB, Baltimore D. HIV-1 gag mutants can dominantly interfere with the replication of the "wild type" virus. Cell 1989;59:113-120.
10. Malim MH, Freimuth WW, Liu J, Boyle TJ, Lyerly HK, Cullen BR, Nabel GJ. Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication. J Exp Med 1992;176: 1197-1201.
11. Baltimore D. Intracellular immunization. Nature 1988;335:395-396.
12. Scaglioni PP, Melegari M, Wands JR. Characterization of hepatitis B virus core mutants that inhibit viral replication. Virology 1994;205:112-120.
13. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995;269: 696-699.
14. Condreay LD, Aldrich CE, Coates L, Mason WS. Efficient duck hepatitis B virus production by an avian liver tumor cell line. J Virol 1990;64:3249-3258.
15. Moore RE, Ausubel FM, Brent R, Kingston DD, Seidman JG, Smith JA, Struhl K Current protocols in molecular biology. New York: Wiley, 1989.
16. Acs G, Sells AM, Purcell RM, Price P, Engle R, Shapiro M, Popper H. Hepatitis B virus produced by transfected HepG2 cells causes hepatitis in chimpanzees. Proc Natl Acad Sci USA 1987;84:4641-4644.
17. Sells MA, Chen ML, Acs G. Production of hepatitis B virus in HepG2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci USA 1987;84:1005-1009.
18. Pugh JC, Yaginuma K, Koike K, Summers J. Duck hepatitis B virus (DHBV) particles produced by transient expression of DHBV DNA in a human hepatoma cell line are infectious in vitro. J Virol 1988;62:3513-3516.
19. Harlow E, Lane D. Antibodies: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor, 1988.
20. Jilbert AR, Wu TT, England JM, del la Hall PM, Carp NZ, O'Connel AP, Mason WS. Rapid resolution of duck hepatitis B virus infection occurs after massive hepatocellular involvement. J Virol 1992;66:1377-1378.
21. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 1990;18:3587-3596.
22. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. Biotechniques 1989;7:980-990.
23. Miller AD, Miller DG, Garcia JV, Lynch CM. Use of retroviral vectors for gene transfer and expression. Methods Enzymol 1993;217:581-599.
24. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high titer helper free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993; 90:8392-8396.
25. Graham FL, Prevec L. Manipulation of adenovirus vectors. Methods Mol Biol 1991;7:109-128.
26. Zhang WW, Fang X, Branch CD, Mazur W, French BA, Roth JA. Generation and identification of recombinant Adenovirus by liposome-mediated transfection and PCR analysis. Biotechniques 1993;15:868-872.
27. Graham FL, Smiley J, Russel WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus 5. J Gen Virol 1977; 36:59-74.
28. McGrory WJ, Bautista DS, Graham FL. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology 1988;163:614-617.
29. Engelhardt JF, Yang Y, Stratford-Pericaudet LD, Allen EA, Kozarsky K, Perricaudet M, Yankaskas JR, et al. Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses. Nature Genet 1993;4:27-34.
30. Horwitz MS. Bidirectional replication of adenovirus type 2 DNA. J Virol 1976;18:307-315.
31. Pugh JC, Zweidler A, Summers J. Characterization of the major duck hepatitis B virus core particle protein. J Virol 1989;63:1371-1376.
32. Schlicht HJ, Bartenschlager R, Schaller H. The duck hepatitis core protein encodes a highly phosphorylated C terminus that is essential for replication but not for RNA packaging. J Virol 1989;63:2995-3000.
33. von Weizsäcker F, Wieland S, Blum HE. Inhibition of viral replication by mutants of the duck hepatitis B virus core protein. HEPATOLOGY 1995;22: 268A.
34. Engelhardt JF, Ye X, Doranz B, Wilson JM. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 1994;91:6196-6200.
35. Yang Y, Nunes FA, Berencksi K, Furth EE, Goenczoel E, Wilson JM. Cellular immunity to viral antigens limits E-1 deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA. 1994;91:4407-4411.